EFFECT-HF Score Calculator for Heart Failure Mortality Risk
The EFFECT-HF score is a simplified clinical tool for predicting 30-day and 1-year mortality in patients hospitalized with heart failure, based on age, comorbidities, and laboratory values.
About
The EFFECT (Enhanced Feedback for Effective Cardiac Treatment) heart failure mortality score was developed by Lee et al. and published in JAMA in 2003 using data from over 2,600 patients hospitalized with heart failure in the EFFECT study. The original score used age, vital signs, laboratory values, and comorbidities to stratify patients into five risk categories for 30-day and 1-year mortality. The simplified version presented here retains the key independent predictors: age >70, elevated BUN (>30 mg/dL), hyponatremia (<136 mEq/L), and comorbidities including dementia, COPD, cirrhosis, and cancer. These variables capture the core domains of risk in heart failure: age-related vulnerability, renal dysfunction (reflected by BUN, a more sensitive marker of cardiorenal syndrome in HF than creatinine), electrolyte disturbance (hyponatremia indicating neurohormonal activation and worse prognosis), and comorbidity burden. The score helps clinicians identify high-risk patients who may benefit from intensive monitoring and advanced heart failure therapies, as well as low-risk patients who may be safely managed on a general medical ward.
Formula
Age >70 (2) + BUN >30 mg/dL (1) + Sodium <136 mEq/L (1) + Dementia (2) + COPD (1) + Cirrhosis (2) + Cancer (2)
The simplified EFFECT-HF score assigns weighted points based on clinical variables independently associated with mortality in heart failure. Age >70 years contributes 2 points. BUN >30 mg/dL (>11.2 mmol/L) contributes 1 point, reflecting the prognostic importance of cardiorenal syndrome. Serum sodium <136 mEq/L contributes 1 point, as hyponatremia in HF indicates neurohormonal activation and worse outcomes. Comorbidities capture additional risk: dementia (2 points), COPD (1 point), cirrhosis (2 points), and cancer (2 points). Total score ranges from 0-11. Higher scores correlate with progressively higher 30-day and 1-year mortality.
Score Interpretation
The EFFECT-HF score provides rapid risk stratification for hospitalized heart failure patients, helping clinicians make appropriate triage decisions. The score identifies patients who may benefit from intensive monitoring and advanced therapies (high/very high risk) versus those who can be managed on general medical wards (low risk). Key clinical applications include guiding ICU admission decisions, determining the intensity of monitoring, identifying patients for advanced HF therapies (inotropes, mechanical circulatory support, transplant evaluation), facilitating goals-of-care discussions, and benchmarking hospital HF outcomes. The components of the score — age, renal function, electrolytes, and comorbidities — are routinely available at presentation, making it practical for real-time clinical use.
Low Risk — 0–2
30-day mortality <5%. Standard HF management appropriate.
Management: Standard heart failure management per ESC/HFSA guidelines. Continue outpatient monitoring.
Moderate Risk — 3–5
30-day mortality 5-15%. In-hospital management recommended.
Management: In-hospital management with close monitoring. Optimize GDMT. Consider cardiology consultation.
High Risk — 6–8
30-day mortality 15-40%. ICU-level care recommended.
Management: ICU-level care. Aggressive diuresis and hemodynamic monitoring. Involve HF specialist.
Very High Risk — 9–11
30-day mortality >40%. ICU care mandatory.
Management: ICU-level care mandatory. Urgent cardiology and critical care consultation. Consider palliative involvement.
Reference Ranges
| Population | Normal Range | Notes |
|---|---|---|
| Hospitalized heart failure patients | 0-11 points | Score 0-2: low risk; 3-5: moderate; 6-8: high; 9+: very high |
Dr. Khaled Hassan
Dr. Khaled is a cardiology consultant with 20 years of experience in managing cardiovascular patients.
View medical review board & editorial policy →Example Calculation
An 82-year-old woman with advanced dementia (bedridden, requiring full care) is admitted with acute decompensated heart failure. She has a history of COPD (on home oxygen) and was diagnosed with metastatic breast cancer 2 years ago (currently on palliative chemotherapy). Laboratory studies: BUN 42 mg/dL, sodium 130 mEq/L, creatinine 1.8 mg/dL. EFFECT-HF calculation: Age >70 (+2), BUN >30 (+1), Sodium <136 (+1), Dementia (+2), COPD (+1), Cirrhosis (0), Cancer (+2) = Total 9/11 — Very high risk category with >40% predicted 30-day mortality. The patient is admitted to the ICU for close monitoring, the palliative care team is involved for goals-of-care discussion, and aggressive life-prolonging measures are avoided in favor of comfort-directed care aligned with patient's advance directives.
Related Conditions
Related Medications
Common Mistakes
Using creatinine instead of BUN for the renal criterion
The EFFECT score specifically uses BUN, not creatinine, as BUN is a more sensitive marker of cardiorenal syndrome in heart failure and has stronger prognostic value for mortality.
Applying the score to chronic stable HF outpatients
The EFFECT-HF score is validated for patients hospitalized with acute decompensated heart failure. It has not been validated for outpatient risk stratification.
Frequently Asked Questions
How does the simplified EFFECT-HF differ from the original score?
Should EFFECT-HF be used to guide end-of-life discussions?
References
- Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290(19):2581-2587. PubMed
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. PubMed
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18):e895-e1032. PubMed